Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

Abstract Aims Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium‐glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim of this...

Full description

Bibliographic Details
Main Authors: Julie Kolwelter, Agnes Bosch, Susanne Jung, Lena Stabel, Dennis Kannenkeril, Christian Ott, Peter Bramlage, Mario Schiffer, Stephan Achenbach, Roland E. Schmieder
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:ESC Heart Failure
Subjects:
Chronic heart failure
Empagliflozin
SGLT2 inhibitor
Vascular function
Central haemodynamics
Blood pressure
Online Access:https://doi.org/10.1002/ehf2.13622

Internet

https://doi.org/10.1002/ehf2.13622

Similar Items